Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Opioid Addiction (November/December) | 2018

View Archived Issues

CME Post-Test - Opioid Addiction, CATR, November/December 2018

November 1, 2018

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

Narcotics Anonymous: What to Tell Your Patients

November 8, 2018

Most of us are pretty familiar with Alcoholics Anonymous (AA), and asking about AA attendance and participation is routine during appointments with patients trying to curb their alcohol use. But what about Narcotics Anonymous (NA)? Read More

Using Medical Management in Treating Opioid Use Disorder

November 8, 2018

Andrew Saxon, MD

To set the stage for understanding medical management, we need to go back about 20 years to the inception of the landmark COMBINE Study. This study was a very large clinical trial for alcohol use disorder (AUD) that compared naltrexone, acamprosate, and their combination, and also looked at two behavioral interventions. Read More

Opioid Treatment Options

November 8, 2018

Opioid use disorder (OUD) treatment can be tricky, in part because it doesn’t respond well to detox and counseling-only approaches. The overwhelming majority of people relapse after such attempts, or even become more vulnerable to overdose because of decreased tolerance after detoxing. Read More

FDA Approves Lucemyra—But Is It Better Than Clonidine?

November 8, 2018

Joshua Sonkiss, MD

On May 16, 2018, the FDA announced its approval of Lucemyra (lofexidine) as a drug to help patients withdraw from opioids. Like clonidine, lofexidine is an alpha-2 agonist, but it is touted as causing less orthostatic hypotension and therefore being somewhat safer to use. Read More